Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a non-standard combination of two products: - A pharmaceutical oral contraceptive (birth control pill), typically containing synthetic estrogen (such as ethinyl estradiol) and progestin (such as norethindrone), used for the prevention of pregnancy. These agents work primarily by inhibiting ovulation, thickening cervical mucus to prevent sperm penetration, and altering the endometrial lining to reduce the likelihood of implantation[2][3][5][6]. - Brevail is a dietary supplement made from standardized flaxseed lignan extract (primarily secoisolariciresinol diglucoside) and sometimes vitamin D3. It is marketed for supporting balanced estrogen metabolism, breast health, and relief from menopausal or PMS symptoms. The mechanism involves providing plant lignans that may modulate estrogen activity in the body[1][4][7]. There are no approved pharmaceutical products combining these two agents into a single formulation; this refers to concurrent use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on birth control + Brevail.